The falling Croda International share price is getting difficult to ignore

The Croda International share price is at its lowest level since 2017. It’s a quality business, but is this a bargain price?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Croda International (LSE:CRDA) is a quality business, but its share price is down 62% from its 2021 highs. And the latest trading update looked ugly at first sight.

Beneath the surface, though, I think there’s reason for optimism. The firm’s life sciences division is still battling a post-Covid hangover, but there are encouraging signs elsewhere.

Company overview

Croda International is a chemicals company. Its products are used in various industries, including crop protection and beauty products, but a key part of the business is life sciences.

The firm makes lipids that enable drugs to be absorbed in the right part of the body. And its products were used in the Pfizer Covid-19 vaccine, which naturally brought a big windfall. 

Since then, though, vaccine demand has evaporated and manufacturers have excess inventories left over. As a result, sales in Croda’s life sciences division have stalled.

The situation has gone from unusually good to unusually bad – but investors might wonder how long this will last. At first sight, the latest results don’t look positive.

Declining sales?

Within Croda’s life sciences business, sales during the first six months of 2024 were 17.7% lower than during the last six months of 2023. That’s not a good sign. 

Excluding £48m in lipid sales for Covid vaccines at the end of last year, sales are still down 2%. In other words, it’s not obvious a return to normality is imminent.

Furthermore, this is set to weigh on profits for the year. Despite other divisions showing growth, operating income is set to be lower than management previously expected.

That’s why the stock is falling. But the decline in overall revenues for the first six months of 2024 obscure an important fact – the company is actually growing.

Growth

Croda International generated £881m in revenues during the first half of 2023, which fell to £816m in the first half of 2024. That’s a 7% decline, but this was due to a weak first quarter this year.

Over the last three months, sales have reached £407.4m. That’s a 0.8% increase on the £404.2m recorded during the second quarter of 2023.

Even with the life sciences division struggling, the overall business is doing well. Investors might have to wait for this to show up at the bottom line, but this is a clear positive.

With the stock at a five-year low, signs of growth might look like a buying opportunity. But there’s one more thing investors should note.

A bargain?

The latest decline takes Croda’s market cap to £5.5bn. But in its best year – when Covid-19 sales were supercharging its life sciences division – the company made £189m in free cash.

That implies a 3.5% return at today’s prices, which I don’t think is particularly exciting. So at today’s prices, the company needs to do more than ever before to look like a bargain.

It might be that this is on the cards, with other parts of the business growing well. But it’s not entirely obvious that the stock is a bargain – even at its lowest level since 2017.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »